Analytical Data
-
Gene name
OSMR
- Application
-
Alternative Names
Interleukin-31 receptor subunit beta
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 85% as determined by SDS-PAGE. as determined by SDS-PAGE.
-
Uniprot
Q99650
-
Expression Region
762-979aa
-
Molecular Weight
31.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OSMR (Oncostatin M receptor) is a member of the interleukin-6 receptor family, playing a crucial role in various physiological processes, including inflammation, hematopoiesis, and development. Research into OSMR has gained momentum due to its involvement in several pathological conditions, such as cancer, autoimmune diseases, and infections. The receptor mediates the effects of oncostatin M, a cytokine that influences cell proliferation, differentiation, and survival. Moreover, OSMR's signaling pathways, particularly those involving Janus kinases (JAKs) and signal transducers and activators of transcription (STATs), are central to understanding the receptor's function in both normal and disease states. Recent studies have highlighted the potential for OSMR as a therapeutic target, as its modulation could provide novel approaches for treating diseases characterized by dysregulated inflammatory responses. Therefore, the development of recombinant OSMR proteins is essential for further elucidating its biological functions, exploring its role in cellular signaling, and assessing its therapeutic potential. The ongoing research into OSMR and its recombinant forms not only aims to expand our understanding of immune regulation and cellular communication but also seeks to pave the way for innovative treatments that harness the biology of this receptor in disease management.
